PACIRA BIOSCIENCES, INC. Tax Withholding Paid on Stock Awards
PACIRA BIOSCIENCES, INC. (PCRX) reported Tax Withholding Paid on Stock Awards of $7.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $3.49M, a 33.91% decline year-over-year.
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $4.36M, a 2306.08% increase year-over-year.
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $143.00K, a 85.71% increase year-over-year.
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $8.00K, a 75.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $5.62M, a 1043.99% increase from fiscal 2024.
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $491.00K, a 363.21% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $106.00K.
- PACIRA BIOSCIENCES, INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.85M 10-Q · filed 2026-08-04 | $7.99M derived: sum of 3 quarters · filed 2026-08-04 | $8.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.36M 10-Q · filed 2026-04-30 | $4.50M derived: sum of 2 quarters · filed 2026-04-30 | $4.51M derived: sum of 3 quarters · filed 2026-04-30 | $9.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $151.00K derived: sum of 2 quarters · filed 2026-02-26 | $5.44M derived: sum of 3 quarters · filed 2026-08-04 | $5.62M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.29M derived: sum of 2 quarters · filed 2026-08-04 | $5.47M 10-Q · filed 2025-11-06 | $5.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.47M 10-Q · filed 2026-08-04 | $5.54M derived: sum of 3 quarters · filed 2026-08-04 | $5.58M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $181.00K 10-Q · filed 2026-04-30 | $258.00K derived: sum of 2 quarters · filed 2026-04-30 | $290.00K derived: sum of 3 quarters · filed 2026-04-30 | $668.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $109.00K derived: sum of 2 quarters · filed 2026-02-26 | $487.00K derived: sum of 3 quarters · filed 2026-02-26 | $491.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $410.00K derived: sum of 2 quarters · filed 2025-11-06 | $414.00K 10-Q · filed 2025-11-06 | $520.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $378.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $382.00K 10-Q · filed 2025-08-05 | $488.00K derived: sum of 3 quarters · filed 2026-02-26 | $488.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.00K 10-Q · filed 2025-05-08 | $110.00K derived: sum of 2 quarters · filed 2026-02-26 | $110.00K derived: sum of 3 quarters · filed 2026-02-26 | $110.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $106.00K derived: sum of 2 quarters · filed 2026-02-26 | $106.00K derived: sum of 3 quarters · filed 2026-02-26 | $106.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $0.00 10-Q · filed 2024-07-30 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |